Who are Arm 1 Everolimus/Reduced dose tacrolimus's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arm-1-everolimus-reduced-dose-tacrolimus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Arm 1 Everolimus/Reduced dose tacrolimus — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Arm 1 Everolimus/Reduced dose tacrolimus (Arm 1 Everolimus/Reduced dose tacrolimus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mTOR inhibitor + Calcineurin inhibitor combination. Area: Immunology / Transplantation.

marketed mTOR inhibitor + Calcineurin inhibitor combination mTOR; Calcineurin (PP2B) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Arm 1 Everolimus/Reduced dose tacrolimus (Arm 1 Everolimus/Reduced dose tacrolimus) — University of Toledo Health Science Campus. Everolimus inhibits mTOR signaling to suppress immune cell proliferation, while reduced-dose tacrolimus inhibits calcineurin to prevent T-cell activation, together reducing organ rejection risk in transplant recipients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arm 1 Everolimus/Reduced dose tacrolimus TARGET	Arm 1 Everolimus/Reduced dose tacrolimus	University of Toledo Health Science Campus	marketed	mTOR inhibitor + Calcineurin inhibitor combination	mTOR; Calcineurin (PP2B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mTOR inhibitor + Calcineurin inhibitor combination class)

University of Toledo Health Science Campus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arm 1 Everolimus/Reduced dose tacrolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/arm-1-everolimus-reduced-dose-tacrolimus. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab